The study showed an overall favorable safety profile for combination therapy in both the MDS and AML populations, with higher remission rates (both complete and partial) in the MDS group compared to the AML group, and some clinical benefit in some patients with adverse risk gene mutations (e.g., TP53). The gene discussed is TP53; the disease is myelodysplastic syndrome.